Pharmacotherapy for Gastrointestinal and Hepatobiliary Disorders
Gastrointestinal (GI) and hepatobiliary disorders affect the structure and function of the GI tract. Many of these disorders often have similar symptoms, such as abdominal pain, cramping, constipation, nausea, bloating, and fatigue. Since multiple disorders can be tied to the same symptoms, it is important for advanced practice nurses to carefully evaluate patients and prescribe a treatment that targets the cause rather than the symptom.Once the underlying cause is identified, an appropriate drug therapy plan can be recommended based on medical history and individual patient factors. In this Assignment, you examine a case study of a patient who presents with symptoms of a possible GI/hepatobiliary disorder, and you design an appropriate drug therapy plan.To PrepareReview the case study assigned by your Instructor for this AssignmentReflect on the patient’s symptoms, medical history, and drugs currently prescribed.Think about a possible diagnosis for the patient. Consider whether the patient has a disorder related to the gastrointestinal and hepatobiliary system or whether the symptoms are the result of a disorder from another system or other factors, such as pregnancy, drugs, or a psychological disorder.Consider an appropriate drug therapy plan based on the patient’s history, diagnosis, and drugs currently prescribed.BELOW IS THE QUESTION———Write a 1-page paper that addresses the following:Explain your diagnosis for the patient, including your rationale for the diagnosis.Describe an appropriate drug therapy plan based on the patient’s history, diagnosis, and drugs currently prescribed.Justify why you would recommend this drug therapy plan for this patient. Be specific and provide examples.BELOW IS THE REQUIRED READING—————-Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.) St. Louis, MO: Elsevier.Chapter 64, “Drugs for Peptic Ulcer Disease” (pp. 589-597)Chapter 65, “Laxatives” (pp. 598-604)Chapter 66, “Other Gastrointestinal Drugs” (pp. 605-616)Chapter 80, “Antiviral Agents I: Drugs for Non-HIV Viral Infections” (pp. 723-743)Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., . . . Sanya, A. J. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328-357. Retrieved from https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.29367This article details the diagnosis and management of nonalcoholic fatty liver disease. Review this article to gain an understanding of the underlying pathophysiology as well as the suggested pharmacotherapeutics that might be recommended to treat this disorder.BELOW IS THE CASE STUDY FOR THIS———————————Utilize the following case study:DC is a 46-year-old female who presents with a 24-hour history of RUQ pain. She states the pain started about 1 hour after a large dinner she had with her family. She has had nausea and on instance of vomiting before presentation.PMH: Vitals:HTN Temp: 98.8oFType II DM Wt: 202 lbsGout Ht: 5’8″DVT – Caused by oral BCPs BP: 136/82HR: 82 bpmCurrent Medications: Notable Labs:Lisinopril 10 mg daily WBC: 13,000/mm3HCTZ 25 mg daily Total bilirubin: 0.8 mg/dLAllopurinol 100 mg daily Direct bilirubin: 0.6 mg/dLMultivitamin daily Alk Phos: 100 U/LAST: 45 U/LALT: 30 U/LAllergies:LatexCodeineAmoxicillinPE:Eyes: EOMIHENT: NormalGI:bNondistended, minimal tendernessSkin:bWarm and dryNeuro: Alert and OrientedPsych:bAppropriate mood CORE SKILL: GI and hepatobiliary disorders present with overlapping symptoms, so the pharmacology must follow a DIAGNOSIS, and the diagnosis must survive a red-flag screen.
GERD/PUD: the acid-suppression ladder — antacids (immediate, brief) → H2 BLOCKERS (famotidine; TACHYPHYLAXIS develops within weeks, which is why they fail as monotherapy for chronic disease) → PROTON PUMP INHIBITORS (omeprazole, pantoprazole — irreversible inhibition of the H+/K+ ATPase; take 30–60 MINUTES BEFORE A MEAL because they only bind ACTIVELY SECRETING pumps, a counseling point that determines whether the drug works at all). PPI long-term risks to counsel on: C. DIFFICILE infection, community-acquired pneumonia, hypomagnesemia, B12 malabsorption, fracture risk, and REBOUND acid hypersecretion on discontinuation (which is why patients feel they “can’t stop”). DEPRESCRIBING PPIs is an exam-worthy topic in its own right.
H. PYLORI: test and treat — the standard regimen is quadruple or triple therapy (PPI + clarithromycin + amoxicillin, or bismuth quadruple therapy), and clarithromycin resistance now drives regimen selection. Confirm eradication with urea breath test or stool antigen (NOT serology, which stays positive after cure — a common error).
RED FLAGS that must precede any empiric acid suppression (this is the graded clinical judgment): dysphagia, odynophagia, unintentional weight loss, GI bleeding/melena, anemia, persistent vomiting, age >60 with new-onset symptoms, family history of GI malignancy. These mandate ENDOSCOPY, not a PPI trial. Also know that NSAIDs and H. pylori are the two dominant causes of peptic ulcer — “stress” is not.
IBD vs. IBS — a distinction the assignment loves: IBD (Crohn’s, ulcerative colitis) is INFLAMMATORY and STRUCTURAL, with objective findings (elevated CRP/fecal calprotectin, endoscopic ulceration, risk of malignancy). Crohn’s — anywhere mouth to anus, SKIP LESIONS, TRANSMURAL (hence fistulas, strictures, abscesses), non-caseating granulomas. UC — continuous, rectum-to-proximal, MUCOSAL only, so no fistulas, but risk of TOXIC MEGACOLON. Treatment: 5-ASA (mesalamine — better for UC), corticosteroids for induction (NOT maintenance), immunomodulators (azathioprine — check TPMT), biologics (anti-TNF: infliximab, adalimumab — screen for LATENT TB AND HEPATITIS B BEFORE STARTING, a mandatory safety step). IBS is a FUNCTIONAL disorder of gut-brain interaction — Rome IV criteria, normal inflammatory markers — treated by subtype (IBS-C: linaclotide, lubiprostone; IBS-D: loperamide, rifaximin, eluxadoline; antispasmodics; low-FODMAP diet; and there is genuine evidence for gut-directed hypnotherapy and CBT, which is not a throwaway).
HEPATOBILIARY: hepatic impairment changes EVERYTHING pharmacologically — reduced first-pass metabolism raises bioavailability, hypoalbuminemia raises free drug fraction, and impaired synthesis of clotting factors raises bleeding risk. AVOID or dose-reduce hepatically metabolized drugs. ACETAMINOPHEN is the key teaching point: safe within limits, but the leading cause of acute liver failure in the US; the maximum is lower in chronic alcohol use and in liver disease; the toxic metabolite is NAPQI, depleting glutathione, and the antidote is N-ACETYLCYSTEINE. Also: hepatic encephalopathy (lactulose, rifaximin), ascites (spironolactone + furosemide), and statin use in liver disease (safer than commonly believed).
ALSO: antiemetics by receptor (ondansetron/5HT3 — QTc prolongation; metoclopramide/D2 — TARDIVE DYSKINESIA with prolonged use, boxed warning; promethazine), and PPI–clopidogrel interaction via CYP2C19 (omeprazole reduces clopidogrel activation — use pantoprazole instead).
Collepals.com Plagiarism Free Papers
Are you looking for custom essay writing service or even dissertation writing services? Just request for our write my paper service, and we'll match you with the best essay writer in your subject! With an exceptional team of professional academic experts in a wide range of subjects, we can guarantee you an unrivaled quality of custom-written papers.
Get ZERO PLAGIARISM, HUMAN WRITTEN ESSAYS
Why Hire Collepals.com writers to do your paper?
Quality- We are experienced and have access to ample research materials.
We write plagiarism Free Content
Confidential- We never share or sell your personal information to third parties.
Support-Chat with us today! We are always waiting to answer all your questions.
